Kalaris Therapeutics
Price & Volume
Stats
See more52W Range | $2.28-$24.15 |
Shares Short | 0 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | $0 |
News
See moreYahoo Finance • 3 days ago
Kalaris stock rating reiterated at Outperform by William Blair
Yahoo Finance • last month
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities
Yahoo Finance • 2 months ago
Kalaris to Participate at Stifel Ophthalmology Forum
Yahoo Finance • 2 months ago
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
About
CEO | Mr. Andrew Oxtoby |
Address | 628 Middlefield Road, Palo Alto, CA, United States, 94301 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 14 |
